Entering text into the input field will update the search result below

Embecta: Not Love At First Sight

Apr. 04, 2022 3:27 AM ETEmbecta Corp. (EMBC)23 Comments
Edward J. Roche profile picture
Edward J. Roche


  • Embecta was spun off from Becton, Dickinson on April 1,2022.
  • It has a solid but very slow growing business in diabetes delivery.
  • While the valuation is modest, there is little to excite the investor from the initial information provided by the company.
Syringes are filled with injection and medical vaccine bottles on a yellow background. Flat lay

5./15 WEST/E+ via Getty Images

Embecta (NASDAQ:EMBC) was spun off on April 1, 2022 from Becton, Dickinson (BDX). The company describes itself as the largest producer of diabetes injection devices with a ~100-year history of reliability and quality. Investors should review the Investor Day

This article was written by

Edward J. Roche profile picture
Edward Roche is the President of Freedom Mountain Investments (http://www.freedommount.com/), an investment firm founded in 2006, located in Paoli, Pennsylvania. Freedom Mountain specializes in identifying hidden value in small and mid size companies before they are recognized by the market. The investment approach is based upon fundamental analysis and places a high emphasis on real and rising financials including sales and earnings. One special approach used to identify a catalyst for release of value is the “Venerable Owner” strategy. This strategy tracks all companies where an older owner owns 40% or more of a company. These situations often lead to sale of the company at a significant premium to market value when the owner seeks to retire. Edward Roche received a Ph. D. degree in Polymer Science and Engineering from the University of Massachusetts and earned an MBA in Finance from the Haub School of Business, St. Joseph’s University, Philadelphia PA. He recently completed a career at the McNeil division of Johnson & Johnson that included high level positions in Business Development and R&D. He is the inventor on 15 US patents in the area of drug delivery and has authored ten scientific publications.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of EMBC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I received shares in Embecta as a result of the spin-off from Becton Dickinson

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.